ReviewHaematologica2015
Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.
Review in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia.Current oncology (Toronto, Ont.) · 2018Guideline
- The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.British journal of haematology · 2016Trial
- BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism.Lymphatics · 2024Article
- The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study.Hematological oncology · 2022Article
- Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study.Haematologica · 2021Article
- O-GlcNAcylation in Chronic Lymphocytic Leukemia and Other Blood Cancers.Frontiers in immunology · 2021Review
- Therapeutic Targets in Chronic Lymphocytic Leukemia.Cancers · 2020Article
- Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance.Cell death & disease · 2020Review
- HIF-1α is over-expressed in leukemic cells fromHaematologica · 2020Article
- Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study.Journal of hematology & oncology · 2019Article
- p66Shc deficiency sets the scene for clinically aggressive chronic lymphocytic leukemia.Haematologica · 2019Article
- Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia.Haematologica · 2019Article
- Clinicohematological parameters and outcomes in a cohort of chronic lymphocytic leukemia patients with Deletion 17p from Pakistan.Blood research · 2018Article
- Design and MinION testing of a nanopore targeted gene sequencing panel for chronic lymphocytic leukemia.Scientific reports · 2018Article
- Ectopic Lck expression in CLL demarcates intratumoral subpopulations with aberrant B-cell receptor signaling.Blood advances · 2018Article
- Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons.Oncotarget · 2017Review
- Article
- EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.Leukemia · 2017Article
- Telomere length analysis in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Binet A.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dramatic advances in next generation sequencing technologies have provided a novel opportunity to understand the molecular genetics of chronic lymphocytic leukemia through the comprehensive detection of genetic lesions. While progress is being made in elucidating the clinical significance of recurrently mutated genes, layers of complexity have been added to our understanding of chronic lymphocytic leukemia pathogenesis in the guise of the molecular evolution and (sub)clonal architecture of the disease. As we prepare for an era of tailored therapy, we need to appreciate not only the effect mutations have on drug response but also the impact subclones containing specific mutations have at initial presentation, during therapy and upon relapse. Therefore, although the wealth of emerging genetic data has great potential in helping us devise strategies to improve the therapy and prognosis of patients, focused efforts will be required to follow disease evolution, particularly in the context of novel therapies, in order to translate this knowledge into clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.